DiaSorin S.p.A. (IT:DIA) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
DiaSorin S.p.A. reported a strong performance for the first nine months of 2024, with revenues reaching €876 million, a 4% increase at constant exchange rates, and an impressive 7% growth excluding COVID-related sales. The company’s adjusted EBITDA also improved, marking a 6% rise, reflecting a robust profitability trend across all business lines, notably in immunodiagnostics and molecular diagnostics. As a result, DiaSorin has raised its revenue guidance for the 2024 financial year, emphasizing continued growth in non-COVID sectors.
For further insights into IT:DIA stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue